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BACKGROUND: Angiogenesis and lymphangiogenesis are considered to play key roles in tumour growth, progression and metastasis.
However, targeting tumour angiogenesis in clinical trials showed only modest efficacy. We therefore scrutinised the concept of
tumour angiogenesis and lymphangiogenesis by analysing the expression of crucial markers involved in these processes in primary
breast cancer.
METHODS: We analysed the expression of angiogenic, lymphangiogenic or antiangiogenic factors, their respective receptors and
specific markers for endothelial and lymphendothelial cells by quantitative real-time RT-PCR in primary breast cancer and compared
the expression profiles to non-cancerous, tumour-adjacent tissues and breast tissues from healthy women.
RESULTS: We found decreased mRNA amounts of major angiogenic and lymphangiogenic factors in tumour compared to healthy
tissues, whereas antiangiogenic factors were upregulated. Concomitantly, angiogenic and lymphangiogenic receptors were
downregulated in breast tumours. This antiangiogenic, antilymphangiogenic microenvironment was even more pronounced in
aggressive tumours and accompanied by reduced amounts of endothelial and lymphatic endothelial cell markers.
CONCLUSION: Primary breast tumours are not a site of highly active angiogenesis and lymphangiogenesis. Selection for tumour cells
that survive with minimal vascular supply may account for this observation in clinical apparent tumours.
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Angiogenesis, the formation of new blood vessels from existing
vasculature, is fundamental in tumour growth, progression and
metastasis (Folkman, 1992). The regulation of tumour angio-
genesis depends on a delicate balance of angiogenic and anti-
angiogenic factors, that can be secreted by both tumour and
stroma cells. In the past years many different proteins have been
identified as angiogenic activators. Foremost among them are
members of the vascular endothelial growth factor (VEGF) family
with seven members (VEGF-A, -B, -C, -D, -E, svVEGF and placenta
growth factor; Takahashi and Shibuya, 2005). Further fibroblast
growth factor-2 (FGF-2, FGF basic) and hepatocyte growth factor
(HGF) have angiogenic activities (Bussolino et al, 1992; Folkman
and Shing, 1992). In the angiopoietin family angiopoietin-1 (ANG-
1) and -2 (ANG-2) can influence the angiogenic process. They bind
both to the receptor TIE-2, but their function in shaping
angiogenesis is very complex and controversial: TIE-2 signalling
could promote or inhibit angiogenesis by influencing survival
of endothelial cells, vessel growth and/or vessel maturation
depending on the balance of ANG-1 and ANG-2, the formation
of different splice variants of the angiopoietins, the presence of
soluble TIE receptors, formation of multimers of the angiopoietins
or dimers of the receptors, interactions with integrins and the
presence of other angiogenic factors such as VEGF-A in the
microenvironment (reviewed in Shim et al, 2007).
Also, members of the platelet-derived growth factor (PDGF)
family can promote angiogenesis as disulphide-linked heterodi-
mers (PDGF-AB) or homodimers (PDGF-AA, PDGF-BB, PDGF-CC
and PDGF-DD) (Yu et al, 2003). Moreover, the chemokines
CXCL1, -2, -3, -5, -6, -7 and -8 can exert angiogenic activity
(Strieter et al, 2006).
Angiogenesis, on the other hand, is also regulated by
antiangiogenic factors. Two important angiostatic factors are
angiostatin and endostatin, which are both produced by proteo-
lytic cleavage of plasminogen or collagen XVIII, respectively
(O’Reilly et al, 1994, 1997). Moreover, thrombospondin-1 (TSP-1)
and thrombospondin-2 (TSP-2) and the chemokines CXCL4,
CXCL9, CXCL10 and CXCL11 can inhibit angiogenesis (Lawler,
2000; Lasagni et al, 2003; Strieter et al, 2006).
Overexpression of angiogenic factors in human cancers has been
described previously, for example, for VEGF-A in lung, breast and
pancreas carcinoma (Yoshiji et al, 1996; Itakura et al, 2000;
Merrick et al, 2005), for FGF-2 in pancreas carcinoma and prostate Received 1 April 2009; revised 3 July 2009; accepted 3 July 2009
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scancer (Yamanaka et al, 1993; Giri et al, 1999) and for ANG-1 and
ANG-2 in gastric and hepatocellular carcinoma (Torimura et al,
2004; Wang et al, 2005). However, there are also reports that
disagree with the concept that tumours produce higher amounts of
angiogenic factors than their normal tissue counterparts: in breast
cancer tissues the expression of FGF-2 was reduced (Luqmani et al,
1992) or did not differ from the expression in normal breast
tissues (Colomer et al, 1997). Furthermore, VEGF-A was similarly
expressed in breast cancer and normal tissues (Soufla et al, 2006).
These inconsistent findings demonstrate that a general upregula-
tion of angiogenic factors in tumours should not be regarded as a
paradigm.
Besides their ability to induce angiogenesis, tumours can also
induce the formation of new lymphatic vessels, a process referred
to as lymphangiogenesis (Wissmann and Detmar, 2006; Karpanen
and Alitalo, 2008). Lymphangiogenesis is mainly stimulated by
VEGF-C and VEGF-D, and also VEGF-A, HGF as well as members
of the FGF, angiopoietin, PDGF and insulin-like growth factor
families can support this process.
Targeting tumour angiogenesis and tumour lymphangiogenesis
are promising therapeutic strategies for the treatment of cancer
and the inhibition of tumour cell dissemination. Antiangiogenic
therapies have been transferred from preclinical to clinical
application in recent years (Ellis and Hicklin, 2008; Kerbel,
2008), but their clinical efficacy is relatively modest and a
therapeutic benefit of VEGF-targeted therapy probably involves
multiple mechanisms, beside its antiangiogenic effect. Considering
the conflicting data for the upregulation of angiogenic factors in
tumours and the limited clinical success of antiangiogenic therapy,
the paradigm of tumours as sites of highly active angiogenesis
needs to be scrutinised. Especially, as most data analysing the
expression of angiogenic factors in tumours are based on
semiquantitative methods such as immunohistochemistry, RNAse
protection assays, northern blots or conventional RT–PCR. Here,
we re-evaluate the concept of tumour angiogenesis and tumour
lymphangiogenesis with quantitative real-time RT-PCR for a
comprehensive set of angiogenic, antiangiogenic and lymphangio-
genic factors, their respective receptors and specific markers for
endothelial cells or lymphatic endothelial cells in primary breast
cancer tissues compared to expression profiles of non-cancerous,
tumour-adjacent tissues and breast tissues from healthy women.
PATIENTS AND METHODS
Patients and tissue samples
The study was approved by the regional ethic board of the Canton
of St Gallen, Switzerland (for breast cancer patients), the
institutional ethic board of the University Hospital Go ¨ttingen,
Germany (for clear cell renal carcinoma) and the Institutional
Review Board of the University of Konstanz, Germany (for healthy
controls) and all patients and controls gave written informed
consent before study entry. We studied 48 female patients
diagnosed with primary breast cancer and 12 healthy controls.
The median ages were 62 years (range 39–89 years) for the
patients and 37 years (range 18–65 years) for the controls. Patients
did not receive any kind of cancer-related pretreatment before the
surgical removal of the tumour. Breast cancer tissue was obtained
from the middle ring of the tumour (see Supplementary Figure S1)
in a macroscopically vital looking area of the tumour by the
pathologist directly after surgical removal of the tumour. Addition-
ally, tumour-adjacent tissue (distance to tumour 1–2cm) was
collected from 41 of these patients. Samples from healthy women
were obtained from breast tissue removed during plastic-aesthetic
reduction surgery. Both types of normal breast tissue were
macroscopically chosen to contain glandular breast tissue and
not only fat tissue. To verify tumour tissue or tumour-free tissue,
respectively, and the absence of necrotic areas cryosections were
obtained from the selected tissue samples and histologically
evaluated by the pathologist.
From the 48 analysed breast tumours, 6 tumours were assigned
grade 1, 30 tumours grade 2 and 12 tumours grade 3 according to
the Elston-modified Bloom and Richardson grading system; 33
tumours were classified as ductal, 8 as mixed ductal-lobular and 7
as lobular. Lymph node metastasis was detected in 21 patients and
41 of the breast cancers were classified as oestrogen receptor-
positive. Overexpression of Her-2/neu was detected with FISH in
six of the tumour tissues.
As a positive control for an angiogenic tumour type, tissues
from clear cell renal carcinoma were analysed from five patients
and compared to tumour-free tissue from the same kidney.
RNA isolation and reverse transcription
A small part of frozen breast tissue (approximately 3 3 3mm)
was homogenised in QIAzol Lysis Reagent (Qiagen, Basel,
Switzerland) and RNA was isolated with the RNeasy Kit plus
additional Dnase digestion (Qiagen) according to the manufac-
turer’s instructions. RNA was reverse transcribed with the High
Capacity cDNA Archive Kit from Applied Biosystems (Rotkreuz,
Switzerland).
Real-time RT-PCR
Real-time RT-PCR analysis was performed with custom designed
TaqMan Low Density Arrays (Applied Biosystems) in 384-well
micro fluidic cards. Details of the chosen assays are given in the
Supplementary Table 1 online. PCR was performed with 100ng of
total RNA converted to cDNA per port in Taqman Universal PCR
Master Mix (2 ) (Applied Biosystems) in a 7900HT Fast real-time
PCR System (Applied Biosystems) with a TaqMan Low Density
Array Upgrade using the following thermal settings: 2min at 501C,
10min at 94.51C and 40 cycles of 30s at 971C, and 1min at 59.71C.
Data from real-time RT-PCR were normalised to the mean of four
different housekeeping genes (B2M, GAPDH, UBC, TBP) and
relative mRNA expression was calculated with the DDCt method.
As calibrator, a cDNA mixture of a tumour, a tumour-adjacent and
a healthy control sample was used.
Immunohistochemistry
Deparaffinised and rehydrated sections (4mm) were microwaved,
endogenous peroxidase was blocked and sections were incubated
with an antibody to CD31 (clone JC/70A; 1:150 dilution; Dako,
Hamburg, Germany) for 25min at room temperature. Binding of
the antibody was visualised with the Dako REAL Detection System,
Peroxidase/DABþ, Rabbit/Mouse (Dako) and sections were
counterstained with haematoxylin.
ELISA measurement of growth factors in serum
From 35 of the 48 breast cancer patients, serum had been collected
at the time of diagnosis. Serum levels of growth factors were
quantified by sandwich ELISA using the respective DuoSet ELISA
Kits (R&D Systems, Abingdon, United Kingdom) according to the
manufacturer’s instructions. Serum samples of 72 healthy women
were used as a control group.
Statistical analysis
Statistical analysis was performed using GraphPad Instat (Instat
Statistics, GraphPad Software). For comparison of tumour,
tumour-adjacent and healthy tissues, two-sided unpaired non-
parametric testing with the Kruskal–Wallis test and Dunn’s
multiple comparisons test as post test was performed. For the
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scomparison of tumour samples and tumour-adjacent tissues from
the same patients paired non-parametric testing with the Wilcoxon
signed rank test was performed. Differences were considered
statistically significant at Po0.05.
RESULTS
Angiogenic and lymphangiogenic factors are
downregulated in breast cancer tissues, whereas
antiangiogenic factors are upregulated
To obtain a comprehensive profile of the major factors regulating
angiogenesis and lymphangiogenesis in breast cancer we analysed
their expression by quantitative real-time RT-PCR in 48 breast
cancer tissues, 41 tumour-adjacent tissues and 12 breast tissues
from healthy women. As the expression of housekeeping genes
could vary considerably between tumour and healthy tissues and
between different donors, we normalised the expression of all
genes to the mean expression of four different housekeeping genes
(GAPDH, UBC, TBP and B2M) to correct for these possible
variations.
To compare the expression profiles of breast cancer and normal
breast tissues, we analysed paired samples of normal and tumour
tissues from 41 patients and calculated the ratio of the expression
in a breast cancer sample to the expression in the tumour-adjacent
tissue of the same patient. Compared to their respective tumour-
adjacent tissues, the breast cancer samples showed a significantly
decreased mRNA expression of all measured angiogenic factors
except for VEGF-A (Figure 1A). The mean expression of ANG-1 in
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Figure 1 Expression of angiogenic, antiangiogenic and lymphangiogenic growth factors and chemokines in primary breast cancer. The mRNA expression
of angiogenic, antiangiogenic and lymphangiogenic growth factors (A) and chemokines (B) was quantified by real-time RT-PCR in breast cancer tissues and
tumour-adjacent tissues of the same patients. The ratio of the expression in tumour tissue to the respective tumour-adjacent tissue was calculated for each
patient. The bars show the mean ratio with s.e.m. for 41 patients. *Po0.05, **Po0.01 and ***Po0.001.
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stumour tissues was reduced to 30% of the expression levels found
in the tumour-adjacent tissues, the expression of ANG-2 was
decreased to 84%, FGF-2 to 17% and HGF to 59%. The PDGF
family was also downregulated in breast cancer samples: compared
to tumour-adjacent tissues the mean expression of PDGF-A was
51%, PDGF-B 87%, PDGF-C 81% and PDGF-D 40% of the
expression levels found in the tumour-adjacent tissues. VEGF-A
was upregulated in 22 tumours (maximum 4.7-fold increase), in 15
tumours downregulated (minimum 3.9-fold decrease) and in 4
tumours expressed in equal amounts as in the tumour-adjacent
tissues. There was no correlation between increased VEGF-A
expression in tumours and lymph node metastasis, tumour
grading or tumour size.
The expression of the other VEGF family members was
downregulated in breast cancer tissues: VEGF-B was reduced to
77%, VEGF-C to 56% and VEGF-D to 4% of the expression in the
tumour-adjacent tissues.
The mRNA expression of angiogenic chemokines was also
downregulated in breast cancer compared to tumour-adjacent
tissues (Figure 1B): for CXCL1, a downregulation to 83% was
observed in the tumour tissues; CXCL2 was reduced to 16%;
CXCL3 to 28%; CXCL5 to 24% and CXCL6 to 24% of the
expression levels in the tumour-adjacent tissues.
A significantly higher mRNA expression of all analysed
antiangiogenic factors was found in the breast cancer samples
compared to tumour-adjacent tissues or healthy tissues (Figure 1A
and B), except for CXCL4, which was decreased to 28% in the
tumour samples. For TSP-1 a 1.6-fold and for TSP-2 a 1.9-fold
higher expression was found in the tumour tissues compared to
tumour-adjacent samples. For the angiostatic chemokines, CXCL9,
CXCL10 and CXCL11, an increased mean expression of 4.7-, 7.4-
and 5.3-fold, respectively, was observed in breast cancer samples
compared to tumour-adjacent tissues.
Supplementary Figure S2 shows the individual expression of the
measured factors and chemokines in all analysed samples. For
these factors and chemokines, no significant difference between
the median expression in tumour-adjacent tissues and breast
tissues from healthy women could be found, except for VEGF-C,
which showed a significant higher expression in tumour-adjacent
tissues.
These data show that the mRNA expression of all angiogenic
factors is downregulated in breast carcinoma with the exception of
VEGF, which was expressed in comparable amounts in tumour
tissues and tumour-adjacent tissues. Conversely, antiangiogenic
factors were upregulated in the tumour. In conclusion, the mRNA
expression profile of angiogenesis-regulating factors is shifted in
the breast cancer microenvironment towards antiangiogenesis, and
the major lymphangiogenic factors VEGF-C and VEGF-D are
downregulated.
The observed antiangiogenic expression pattern in breast cancer
tissues may be explained by two different hypotheses. Tumour
progression may select for tumour cells able to grow without
optimal vascular supply so that at the time of diagnosis and
surgery the angiogenic microenvironment in the tumour could
have disappeared. As an alternative model, the tumour micro-
environment could become increasingly angiogenic as tumour
progression proceeds and tumours become more aggressive. In
this case the analysed tumours would have been excised before
they had developed an angiogenic environment. To test these
hypotheses we compared the median expression of more
aggressive tumours with a histopathologic grading of 3 to less
aggressive tumours with grade 1 (Figure 2). For FGF-2, we found
significant lower mRNA levels (2.3-fold) in grade 3 tumours than
in grade 1 tumours. For most other angiogenic factors, we
observed a lower expression in grade 3 tumours than in grade 1
tumours but these differences were not significant. For VEGF-A,
PDGF-D and the angiogenic chemokines, no difference was
found between tumours with different grading. Interestingly, the
antiangiogenic chemokines CXCL9, CXCL10 and CXCL11 were
more expressed in grade 3 tumours than in grade 1 tumours. These
data indicate that the antiangiogenic environment is more
pronounced in aggressive tumours supporting the hypothesis that
the observed antiangiogenic shift results from selection of tumour
cells that can grow with low vascularisation and do not produce
angiogenic factors anymore.
To verify the validity of our real-time RT-PCR approach we
analysed clear cell renal carcinoma, a tumour type known to be
highly angiogenic (Turner et al, 2002). As expected, we found
a strong upregulation of VEGF-A in the tumour tissues
(Supplementary Figure S3). Compared to normal kidney tissues,
the median expression of VEGF-A was 8.9-fold increased in the
renal cancer tissues. Also, PDGF-D was significantly upregulated
(3.7-fold) in renal cell carcinoma. ANG-2 mRNA was found in
higher amounts in the tumour tissues, but this difference was not
significant. VEGF-B, HGF and PDGF-C were downregulated in
renal carcinoma, whereas the other analysed angiogenic and
antiangiogenic factors were expressed in comparable amounts.
This analysis showed that our real-time RT-PCR assay can also
detect an angiogenic tumour microenvironment. Thus the
observed antiangiogenic profile of breast cancer tissues cannot
result from a technical shortcoming of the detection method.
The gene expression profiles showed a diminished expression of
the main angiogenic and lymphangiogenic factors in breast cancer.
To investigate whether this difference is also detectable on protein
levels we performed ELISA measurements of the most important
factors in homogenates of breast cancer tissues and normal
tumour-adjacent tissues of the same donors (Supplementary
Figure S4). Similar amounts of VEGF-A, FGF-2 and PDGF-AA
were present in tumour and tumour-adjacent tissues. ANG-1 and
VEGF-D were detected significantly less in breast cancer than in
the tumour-adjacent tissues (3.2-fold and 2-fold less). The
downregulation of FGF-2 and PDGF-A in the tumour tissues on
mRNA level was not reflected in the protein data. As these
cytokines are secreted soluble proteins, diffusion and transport by
lymph or blood into the tumour tissue could balance the
differences in protein production. The downregulation of ANG-1
and VEGF-D was also seen on protein level, but was not as
pronounced as on the mRNA level.
Receptors of angiogenesis and lymphangiogenesis are
downregulated in breast cancer tissues
For the regulation of angiogenesis, not only the expression of
growth factors is important, but also the expression of the
respective receptors. Therefore, the mRNA expression of receptors
for angiogenic and lymphangiogenic factors was analysed by
quantitative real-time RT-PCR and the ratio of the expression in a
breast cancer sample to the expression in the tumour-adjacent
tissue of the same patient was calculated (Figure 3). The VEGF
receptors were downregulated in breast cancer tissues compared to
the respective tumour-adjacent tissues: the mean VEGF-R1 (FLT1)
expression in the tumour tissue was reduced to 47%, VEGF-R2
(KDR) to 49% and VEGF-R3 (LT4) to 49% of the expression levels
in tumour-adjacent tissues. For neuropilin-1 (NRP-1) and
neuropilin-2 (NRP-2), which can act as enhancers for VEGF-R
signalling, we found a mean decrease of NRP-1 in breast tumour
tissue to 55% of the expression levels in tumour-adjacent tissues,
whereas NRP-2 expression showed no significant difference
between tumour and tumour-adjacent tissues. The angiopoietin
receptor TIE-2 was reduced to 40% in breast cancer tissues
compared to tumour-adjacent tissues. For the two PDGF receptors,
PDGF-Ra and PDGF-Rb, the mean expression in breast cancer
samples was reduced to 41 and 72% of the expression levels found
in tumour-adjacent tissues. CXCR2, the receptor for angiogenic
chemokines, was reduced in the breast cancer tissues to 56% of the
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slevel in the-adjacent tissues, whereas CXCR3, the receptor for
angiostatic chemokines, was upregulated 3.4-fold.
Supplementary Figure S5 shows the individual expression of the
measured receptors in all analysed samples. For these receptors no
significant difference between the median expression in tumour-
adjacent tissues and breast tissues from healthy women could be
found.
Concomitant with the reduced expression of angiogenic factors,
the expression of angiogenesis-inducing receptors also was down-
regulated in the breast tumours. Moreover, the major lymphangio-
genic receptor VEGF-R3 was downregulated.
Markers for endothelial and lymphatic endothelial cells are
downregulated in breast cancer tissues
It has been previously described that the measurement of the
expression of endothelial markers such as CD146 by quantitative
real-time PCR in tumour samples correlated with microvessel
density assessed by immunohistology (Loges et al, 2007). We
therefore determined the amount of endothelial cells in tumours or
normal tissues by real-time RT-PCR analysis of two endothelial
markers, CD146 and VE-Cadherin and lymphatic endothelial cells by
analysing the expression of two specific lymphatic endothelial
markers, lymphatic vessel endothelial hyaluronan receptor 1
(LYVE1) and Prospero-related homeobox 1 (PROX1; Figure 4A).
The endothelial cell markers CD146 (MCAM) and VE-Cadherin
showed a decreased expression in the tumour tissues compared to
tumour-adjacent or healthy breast tissues: for CD146 the mean
expression in tumour tissues was reduced to 44%, and for
VE-Cadherin to 40% of the expression levels in the respective
tumour-adjacent tissues. The distribution of blood vessels in tumour
and tumour-adjacent breast tissues was also analysed by immuno-
histochemical staining for CD31 in paraffin sections (Figure 4B). The
CD31 staining confirmed the real-time RT-PCR data: also, the
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Figure 2 Comparison of expression levels of angiogenic, antiangiogenic and lymphangiogenic growth factors, and chemokines in primary breast cancer
according to histopathologic grading. Relative expression data for the different growth factors and chemokines were analysed according to the
histopathologic grading of the primary breast tumours. The horizontal line indicates the median of each group. *Po0.05.
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simmunohistochemical detection of blood vessels showed a decreased
vessel density in the tumour compared to the normal breast tissues.
Also, both lymphatic endothelial markers, LYVE1 and PROX1,
were less expressed in the tumour compared to tumour-adjacent
tissues (Figure 4A): for PROX1, the mean expression in the
tumours was reduced to 21%, for LYVE1 even to 6% of the
expression levels in the tumour-adjacent tissues. These data
indicate that the amounts of endothelial and lymphatic endothelial
cells in breast tumour tissues are lower than those in tumour-
adjacent or healthy breast tissues and reflect the reduced amounts
of angiogenic and lymphangiogenic factors and the increased
expression of antiangiogenic factors in the breast cancer samples.
Supplementary Figure S6 shows the individual expression of the
measured markers in all analysed samples. For these markers no
significant difference between the median expression in tumour-
adjacent tissues and breast tissues from healthy women could be found.
Noteworthy, grade 3 tumours showed a lower expression of
CD146, VE-Cadherin, LYVE1 and PROX1 than grade 1 tumours
indicating that the amount of endothelial cells and lymph
endothelial cells is further reduced with increasing tumour
aggressiveness (Supplementary Figure S7).
The suitability of the selected endothelial markers in the real-
time RT-PCR assay to assess tissue vascularisation was confirmed
with the clear cell renal carcinoma tissues (Supplementary Figure
S8). These highly vascularised tumours (Turner et al, 2002)
showed a significant increase in the amounts of CD146 (fourfold)
and VE-Cadherin (twofold) mRNA in comparison to normal
kidney tissues reflecting the higher numbers of endothelial cells in
the tumours.
Angiogenic factors are decreased in the sera of breast
cancer patients whereas antiangiogenic factors are elevated
The levels of angiogenic factors in blood have been considered as
surrogate markers for tumour angiogenesis. We therefore analysed
the concentration of several angiogenesis-regulating factors in
the sera of 35 breast cancer patients at the time of diagnosis
and compared them to serum levels found in 72 healthy women.
ANG-1, HGF and PDGF-AB were found in significant lower levels
in the sera of breast cancer patients than in healthy controls
(Figure 5). VEGF-A was present in similar amounts in the sera of
patients and controls. However, endostatin, a potent angiostatic
factor, was significantly increased (1.4-fold) in the sera of breast
cancer patients. This increase has been described before (Kuroi
et al, 2001) and further corroborates the finding that the
production of antiangiogenic factors is elevated in breast tumours.
The concentrations of ANG-2 and FGF-2 were below the detection
limits of the respective ELISAs. Our real-time RT-PCR data
demonstrate that breast tumours do not produce increased
amounts of angiogenic factors. In accordance to these data, we
found no elevated levels of these factors in the sera of patients.
Taken together, these findings indicate that primary breast
tumours are not a significant source of angiogenic growth factors.
In contrast, the tumours release angiostatic factors as endostatin.
These tumour-derived angiostatic molecules could be responsible
for the systemic downregulation of angiogenic factors as ANG-1,
HGF or PDGF-AB, which were decreased in the sera of breast
cancer patients.
DISCUSSION
Angiogenesis is considered as a limiting factor in tumour growth.
Cancer cells require access to blood vessels for adequate supply of
oxygen and nutrients. To gain this access, tumour and stroma cells
can release mediators in the neoplastic microenvironment to
induce migration and proliferation of endothelial cells resulting in
the formation of new blood vessels. We studied the expression of
these mediators and their respective receptors in primary breast
cancer by quantitative real-time RT-PCR. Our data showed
reduced expression of most angiogenesis-inducing factors in
breast cancer tissues compared to non-cancerous, tumour-
adjacent tissues and breast tissues from healthy women, whereas
angiogenesis inhibitors were expressed in higher amounts in the
tumours. VEGF-A was the only angiogenic factor expressed in
similar amounts in tumour tissues and normal tissues. These
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sfindings were unexpected because tumours are generally con-
sidered as sites of active angiogenesis with high expression of
angiogenic factors. Especially, high expression of VEGF-A is
expected in tumours because the transcription of VEGF-A is
increased by the transcription factor hypoxia-inducible factor 1
(HIF-1), which is stabilised in the hypoxic tumour environment
(Shweiki et al, 1992; Liu et al, 1995).
Our real-time RT-PCR analysis revealed that not only the
balance of angiogenic and antiangiogenic factors was shifted
towards antiangiogenesis, but also the receptors for the angiogenic
factors were expressed to a lesser extent in the cancer tissues
than in normal tissues. All three VEGF receptors (VEGF-R1, -R2
and -R3) were downregulated as well as its coreceptor NRP-1, both
PDGF receptors and the chemokine receptor CXCR2, which is
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sactivated by angiogenic chemokines. This receptor downregulation
in the tumours is expected to result in a reduced responsiveness
towards angiogenic stimuli. On the other hand, the chemokine
receptor CXCR3, the receptor for angiostatic chemokines CXCL4,
CXCL9, CXCL10 and CXCL11, was upregulated.
The antiangiogenic microenvironment and the downregulation
of angiogenic receptors in the tumours were also reflected in the
reduced number of endothelial cells. It may be counterintuitive
that tumours exhibit lower microvessel densities than the
corresponding normal tissues, but this has been described for
breast, lung, renal cell and colon carcinomas (Eberhard et al,
2000). An immunohistochemical analysis showed a 35% higher
microvessel density in corresponding normal breast tissues
compared to mammary carcinoma (Eberhard et al, 2000). This
finding could be explained by the lower oxygen consumption rate
of tumour cells (Steinberg et al, 1997) and their resistance to
apoptosis under hypoxic conditions (Graeber et al, 1996). As
tumour cells are viable at lower oxygen concentrations, they can
survive at greater distances from the vasculature than normal cells
(Hlatky et al, 2002). The observed antiangiogenic tumour
environment and decreased number of endothelial cells in breast
cancer may result from a constant selection process during disease
progression for tumour cells tolerating minimal vascular supply.
For these tumour cells, the expression of angiogenic factors is
dispensable. Consequently, at the time of diagnosis and surgery the
angiogenic microenvironment in the tumour could have disap-
peared. This model is supported by the fact that more aggressive
tumours (grade 3) showed an even less angiogenic expression
profile and less endothelial cells than grade 1 tumours. The strict
dependence of tumour growth on neoangiogenesis could be
limited to the early phase of tumour growth, during the
‘angiogenic switch’. Once the tumour has established, tumour
cells can grow into solid neoplasms by exploiting the host’s
preexisting vessels, without the need for new blood vessel
formation, especially in vessel-dense organs. This ‘co-opting’ of
vessels could lead to tumour progression even in the absence of
neoangiogenesis (Leenders et al, 2004).
Data that show highly activated angiogenesis in tumours are
mainly data from mouse tumour models and the upregulated
angiogenesis in these tumours could be a specialty of these animal
models. The subcutaneous space where experimental tumours are
generally transplanted is essentially avascular, and tumours are
therefore forced to induce angiogenesis to grow in this anatomical
location (van Kempen and Leenders, 2006). Due to this experi-
mental preselection of angiogenesis-competent tumours these
mouse models may not reflect angiogenesis in natural growing
tumours. It remains to be clarified if the antiangiogenic and
antilymphangiogenic tumour microenvironment of primary hu-
man breast cancer is also found in tumours of other organs and in
the metastases of the primary tumours.
Studies in animal tumour models and clinicopathological data
have indicated that lymphangiogenesis in the vicinity of solid
tumours may contribute to lymphatic metastasis (Skobe et al,
2001; Mattila et al, 2002; Nakamura et al, 2005). An activation of
lymphangiogenesis by tumour-derived factors might be of high
importance in breast cancer because it metastasises primarily via
lymphatic vessels. Our data showed a reduced expression of the
lymphangiogenic factors, VEGF-C and VEGF-D, and their
respective receptor VEGF-R3 in the breast cancer tissues compared
to normal breast tissues. In addition, other lymphangiogenic and
angiogenic factors as FGF-2, HGF, angiopoietins and members of
the PDGF family were downregulated. The diminished production
of lymphangiogenic factors was also reflected by a reduced amount
of lymphatic endothelial cells in the tumour samples. These data
indicate that lymphangiogenesis is not increased in breast cancer
tissues, but is even less activated than in normal breast tissues.
This finding is in agreement with several other reports about
lymphangiogenesis in human breast cancer: a reduction or even
absence of lymphatic vessels has been described in the tumour
area compared to normal breast tissues; also, a proliferative
activity of the lymph vessels in the tumours was not detectable
(Williams et al, 2003; Vleugel et al, 2004; Agarwal et al, 2005). For
VEGF-C we found elevated expression in the tumour-adjacent
tissues. But there was no correlation between VEGF-C expression
in tumour-adjacent tissues and lymph node metastasis.
A previous study showed with immunohistochemistry an elevated
number of VEGF-R3-positive blood vessels in breast tumours
compared to corresponding normal breast tissues (Valtola et al,
1999). Further, the immunostaining for VEGF-C varied strongly
among different invasive carcinoma samples, with some samples
showing strong expression of VEGF-C whereas other stained only
very weak or not at all. These findings can be reconciled with our
data. With the real-time RT-PCR data we found a downregulation of
VEGF-R3 expression in the total tumour mass, we cannot distinguish
between the expression in the different cell types. As we see a
reduction of endothelial cells in the tumour tissues, the decreased
expression of VEGF-R3 (and those of other angiogenic receptors)
could be due to the lower amounts of endothelial cells and not due to
a downregulation per endothelial cell. Even an upregulation of
VEGF-R3 per endothelial cell, but reduced numbers of endothelial
cells in total, could lead to this result.
Our data show that the production of angiogenic and
lymphangiogenic factors is reduced in human breast cancer
tissues, and accordingly also the amounts of endothelial and
lymphatic endothelial cells in the tumour. The antiangiogenic
environment in breast tumours has several pivotal clinical
implications. First, this finding could explain the modest efficacy
of anti-VEGF therapies in breast cancer. Combination of standard
chemotherapies with a VEGF-neutralising antibody (bevacizumab)
increased response rates or prolonged progression-free survival,
but did not prolong overall survival in metastatic breast cancer
patients (Miller et al, 2005, 2007). As primary breast tumours seem
to grow without an upregulated expression of VEGF-A, blockade of
VEGF-A signalling cannot be expected to strongly impair further
tumour growth. As anti-VEGF therapies can also induce ‘normal-
isation’ of tumour vessels and thus improve delivery of
chemotherapeutics, this alternative mode of action could account
for the observed clinical benefit in combination with standard
chemotherapy (Jain, 2005; Dickson et al, 2007).
Further we have shown that primary breast tumours are
predominantly a source of antiangiogenic factors and do not
produce high amounts of angiogenic factors. An elimination of the
primary tumour would reduce the amounts of antiangiogenic
factors in the blood, whereas the formation of angiogenic factors
would be stimulated after surgery in the wound healing process.
The shift in the angiogenic balance could lead to a systemic
activation of angiogenesis flaring up neovascularisation for
micrometastases and thus breaking their dormant state. An
activated outgrowth of metastases after the removal of the primary
tumour has been described in animal tumour models and cancer
patients (O’Reilly et al, 1994; Peeters et al, 2006). It was also
reported that the surgical removal of primary colorectal cancers
resulted in decreased plasma levels of angiostatin and endostatin
and an increased metabolic activity of liver metastases indicating
vessel neoformation (Peeters et al, 2005). To substitute the
tumour-derived antiangiogenic factors, a long-term therapy with
antiangiogenic factors could be a promising strategy to limit
progression of the disease after surgery.
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